异柠檬酸脱氢酶1基因突变与临床低级别胶质瘤预后的关系

数据集获取（Figshare）

• 源站标题：<i>Isocitrate dehydrogenase 1</i> Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
• DOI：10.1371/journal.pone.0130872
• 发布日期：2015-06-26
• 文件数：3 个
• 文件总体积：76.46 KB
• 源站页面：https://plos.figshare.com/articles/dataset/_Isocitrate_dehydrogenase_1_Gene_Mutation_Is_Associated_with_Prognosis_in_Clinical_Low_Grade_Gliomas/1465093

命令行下载

curl -L -o "S1_Table.docx" "https://ndownloader.figshare.com/files/2150733"
curl -L -o "S2_Table.docx" "https://ndownloader.figshare.com/files/2150734"
curl -L -o "S3_Table.docx" "https://ndownloader.figshare.com/files/2150735"

文件清单

• S1_Table.docx（18.71 KB）
• S2_Table.docx（30.84 KB）
• S3_Table.docx（26.92 KB）

文件总体积 76.46 KB（源站 API 实测）。

数据说明

Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas. However, their prognostic significance in low-grade gliomas remains controversial. We determined the predictive and prognostic value of isocitrate dehydrogenase 1 status in low-grade gliomas. The association of isocitrate dehydrogenase 1 status with clinicopathological and genetic factors was also evaluated. Clinical information and genetic data including isocitrate dehydrogenase 1 mutation, O 6-methylguanine DNA methyltransferase promoter methylation, 1p/19q chromosome loss, and TP53 mutation of 417 low-grade gliomas were collected from the Chinese Glioma Genome Atlas database. Kaplan–Meier and Cox proportional hazards regression analyses were performed to evaluate the prognostic effect of clinical characteristics and molecular biomarkers. Isocitrate dehydrogenase 1 mutation was identified as an independent prognostic factor for overall, but not progression-free, survival. Notably, isocitrate dehydrogenase 1 mutation was found to be a significant prognostic factor in patients with oligodendrogliomas, but not in patients with astrocytomas. Furthermore, O 6-methylguanine DNA methyltransferase promoter methylation (p = 0.017) and TP53 mutation (p isocitrate dehydrogenase 1-mutated tumors than in isocitrate dehydrogenase 1 wild-type tumors. Younger patient age (p = 0.041) and frontal lobe location (p = 0.010) were significantly correlated with isocitrate dehydrogenase 1 mutation. Chemotherapy did not provide a survival benefit in patients with isocitrate dehydrogenase 1-mutated tumors. Isocitrate dehydrogenase 1 mutation was an independent prognostic factor in low-grade gliomas, whereas it showed no predictive value for chemotherapy response. Isocitrate dehydrogenase 1 mutation was highly associated with O 6-methylguanine DNA methyltransferase promoter methylation and TP53 mutation.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0130872（source: https://plos.figshare.com/articles/dataset/_Isocitrate_dehydrogenase_1_Gene_Mutation_Is_Associated_with_Prognosis_in_Clinical_Low_Grade_Gliomas/1465093）。